Literature DB >> 10629020

Effect of conalbumin on the activity of Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC beta-lactamases.

G S Babini1, D M Livermore.   

Abstract

Syn 2190, a 1,5 dihydroxy-4-pyridon monobactam inhibitor of AmpC enzymes, was tested against beta-lactamase-producing bacteria with piperacillin, piperacillin-tazobactam and ceftazidime as partner drugs. In the presence of conalbumin as an iron chelator, Syn 2190 potentiated these drugs against most AmpC producers, although Klebsiella spp. with plasmidic AmpC enzymes were an exception. Potentiation was much weaker without conalbumin, suggesting that Syn 2190 exploits a ferric uptake pathway, as do catecholic cephalosporins. Syn 2190 had little ability to potentiate partner drugs against strains with other beta-lactamase types but, with conalbumin, increased the activity of piperacillin-tazobactam against Escherichia coli transconjugants producing various class A or D enzymes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629020     DOI: 10.1093/jac/45.1.105

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

1.  In vitro and in vivo activities of AM-112, a novel oxapenem.

Authors:  Conor E Jamieson; Peter A Lambert; Iain N Simpson
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 2.  Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.

Authors:  Carine Bebrone; Patricia Lassaux; Lionel Vercheval; Jean-Sébastien Sohier; Adrien Jehaes; Eric Sauvage; Moreno Galleni
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

Review 3.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

4.  The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics.

Authors:  Malcom G P Page
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.